Emily Bonacquisti

Emily Bonacquisti joined Flagship Pioneering in 2025 and serves as an Associate within the Pipeline and Product Innovation team. As part of Flagship’s P&PI team, Emily works alongside colleagues who use their strong understanding of disease and translational biology to support the creation and evolution of pipeline strategies that capitalize on Flagship’s ecosystem of innovative platform technologies.

Emily previously held roles in biotech equity research at H.C. Wainwright & Co. and in R&D at the MIT-based startup VitaKey. At VitaKey, she developed oral therapeutics for gastrointestinal diseases, environment-remediating probiotics, as well as led teams that secured significant non-dilutive funding from the NIH, ARPA-H, and DOD. She received a Bronze Star award from Shee Akita Government Services for her outstanding work on leading projects relevant to military performance.

Emily received her Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill. Her Ph.D. research was directed at the interface of drug delivery, RNA engineering, and molecular biology, where she focused on developing an RNA-based platform technology to track the movement of extracellular vesicles and cargo in cancer, diabetes, and autoimmune disease.

She received her B.S. with honors in biological sciences from the University at Buffalo with a concentration in cell and molecular biology, where her time was spent establishing brain pharmacokinetic models of monoclonal antibodies, studying RNA regulatory circuits in model bacterial genetics systems, and working in the bacteriology/virology group at Zeptometrix.